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Effector cell mediated cytotoxicity measured by intracellular 
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CD8+ cytotoxic T lymphocyte (CTL) activity is currently believed to be one of the key immunologic mechanisms responsible for the 
prevention or attenuation of HIV-1 infection. The induction of CD8+ T cell activation may also result in the production of soluble or 
non-classical lytic factors that are associated with protection from infection or slower disease progression. Traditionally, CD8+ CTL 
responses have been measured by the classic chromium release assay, monitoring the ability of T cells (Effector cells) to lyse 
radiolabelled HLA – matched “target cells” that express the appropriate antigen-MHC complex. This method is not only labor 
intensive, semi quantitative assay at best, but also needs fresh, non-cryopreserved cells. Recently, cytokine specific ELISPOT assays or 
tetrameric MHC-I/ peptide complexes have utilized to directly quantitate circulating CD8+ effector cells, and these assays are more 
sensitive, quantitative and reproducible than the traditional CTL lysis assay and can also be performed on cryopreserved cells. Although 
these are reproducible assays for the assessment of soluble antiviral activity secreted by activated T cell populations they can be 
extremely expensive to perform. We have used FACS Analysis to measure Granzyme B release as a function of cell mediated 
cytotoxicity. This method helps quantitate the CTL activity and also identifies the phenotype of the cells elucidating this immune 
response. The method described not only monitors immunological response but also is also simple to perform, precise and extremely 





Cytotoxic T lymphocytes (CTL) act as mediators of destruction 
of immune function during HIV infection (1). Human 
immunodeficiency virus (HIV) – specific cytotoxic T cell 
lymphocytes (CTL) play a major role in control of viral 
replication, however a complete understanding of the specific 
epitopes targeted by CTL is essential to assess this antiviral 
response (1). Naïve T cells are activated to proliferate and 
differentiate into armed effector cells by recognition of a foreign 
peptide fragment bound to a self-MHC molecule and delivery of 
co-stimulatory signals by antigen presenting cells. The effector 
cells are triggered when their antigen specific receptors and either 
the CD4 or the CD8 co- receptors bind to the peptide: MHC 
complex on a target cell. Effector T cells can mediate a variety of 
functions. Some of the functions are killing of infected cells by 
the CTLs and the activation of the macrophages by the Th1 cells 
which together make up cell – mediated immunity (1, 2). 
Cytotoxic T lymphocytes (CTL) function to destroy cells that 
express foreign antigens. CTL play an important role in the Mahajan et al.    
 
 
Biological Procedures Online • Vol. 5 No. 1 • September 5, 2003 • www.biologicalprocedures.com 
183 
elimination of virally infected cells. The majority of virus-specific 
CTL are CD8+. In contrast to CD4+ helper cells, which 
recognize antigen presented in the context of class II major 
histocompatibility complex (MHC) molecules, CTL recognize 
antigens in the context of class I MHC molecules. The 
importance of this distinction is that most of the time antigens 
need to be produced inside the cell in order to be presented by 
class I molecules. By contrast, antigens presented by class II 
MHC molecules can be taken up by antigen presenting cells, 
processed, and then presented to CD4+ cells. Assays for 
detection of CTLs have relied on direct determination of cell lysis 
as measured by the classical assay for CTL activity namely the 
chromium release assay (1, 3). Effector Cytotoxic T Lymphocytes 
(CTL) bind targets (infected cells) bearing virus peptide on 
syngenic (self) Class I MHC and signal the targets to undergo 
apoptosis. If the targets are labeled with 51Chromium before the 
CTL are added, the amount of 51Cr released into the supernatant 
is proportional to the number of targets killed. HIV-specific lysis 
is calculated by comparing lysis of target cells expressing HIV or 
control antigens in the presence or absence of patient effector 
cells, and is usually expressed as the % HIV-specific lysis. Percent 
specific cytotoxicity is calculated by (specific release - 
spontaneous release) ÷ (maximum release - spontaneous release) 
and may be 20%-85% for a positive assay. Percent specific 
cytotoxicity is usually determined at several ratios of effector 
(CTL) to target cells (E:T). While this assay measures an effector 
characteristic of CD8+ T cells, it is cumbersome and technically 
difficult to perform. Additionally, the standard lytic assay is 
qualitative and must rely on a limiting dilution analysis (LDA) for 
quantitative results, and the LDA frequently underestimates the 
true level of CTL response. One of the major limitations of the 
assay is that the frequency of specific CTL is very low in a 
primary response and CTL are difficult to activate in vitro. For 
these reasons, the 51Cr release assay is usually done with cells 
stimulated in vivo. Although CTL can each kill many targets in vivo, 
in vitro this assay requires numbers of CTL equal to or greater 
than the number of targets for detectable killing (3). 
 
In recent years, newer assays allowing for easier assessment of 
CTL responses have been developed. Yet another method of 
measuring cytotoxicity, is the ELISPOT assay where the CD8+ 
CTL response, which can be assessed by measuring IFN-γ 
production by HIV-specific effector cells, is quantitated by 
measuring the number of Spot Forming Units (SFU) under a 
stereomicroscope (4). In this assay, antigen-presenting cells 
(APC) are immobilized on the plastic surface of a micro titer 
well, and effector cells are added at various effector:target ratios. 
The binding of APC's by antigen-specific effector cells triggers 
the production of cytokines including IFN-γ by the effector cells 
(5). More recently a method for quantifying the number of 
circulating antigen-specific CD8+ T cells namely the tetramer 
assay is being increasingly used to measure CTL activity. In this 
assay, a specific epitope is bound to synthetic tetrameric forms of 
fluorescent labeled MHC Class I molecules. Since CD8+ T cells 
recognize antigen in the form of short peptides bound to Class I 
molecules, cells with the appropriate T cell receptor will bind to 
the labeled tetramers and can be quantified by flow cytometry. 
Although this method is less time-consuming than the ELISPOT 
assay, the tetramer assay measures only binding, not function. 
Not all cells that bind a particular antigen necessarily become 
activated. Also diversity of both HIV-1 and host MHC alleles can 
affect cellular immune responses. MHC alleles differ in the 
specific epitopes they present to T cells (4, 6, 7). These 
differences, which presumably could influence cytolytic and 
helper T cell responses, are thought to explain data correlating 
different HLA alleles with different rates of clinical progression.  
 
The method outlined in this manuscript is based on the fact that 
the two dominant mechanisms of lymphocyte- mediated 
cytotoxicity are the perforin /granzyme mediated killing and the 
death receptor – mediated killing (8). The perforin- dependent 
pathway is dominant in CD8+ CTL and natural killer  (NK) cells. 
The death receptor mediated pathway appears to be active in all 
killer cell lineages but most important for CD4+ cells, especially 
those of the Th1 phenotype. Cytoplasmic granules from activated 
natural killer (NK) and Cytotoxic T lymphocytes (CTL) contain a 
pore forming protein, perforin and several homologous serine 
proteases called Granzymes (8). Granzyme B is known to be 
present in the cytotoxic granules of NK cells and activated CTLs 
with cytotoxic potential. Thus a methodology based on 
measurement of cell mediated cytotoxicity as a function of 
Granzyme B release by effector cells and simultaneous analysis of 
effector cell phenotype as well as viability in the same sample by 
flow cytometry under conditions that ensure reliable 
discrimination of target and effector cells would be ideal in 
monitoring patients immune response. The basic principle of 
simultaneous analysis of cell mediated cytotoxicity and effector 
cell phenotype by flow cytometry was adapted from a method by 
Derby et al. (9). Although the various assays for measuring CTL 
have improved over the last five years, many are performed only 
in research laboratories and have not been validated for clinical 
use. 
 
MATERIALS AND METHODS 
 
Cells from a HIV-1 transfected human T-cell line 8E5/LAV   
(Catalog # 95, AIDS Research and Reference reagent program 
catalog, NIH, Rockville, MD) were used as target cells and the 
PBMC isolated from the HIV patients and non-HIV controls 




The 8E5/LAV target cells were cultured in phenol-red free 
RPMI 1640 complete media supplemented with 10% FCS, 2mM 
glutamine, 1mM pyruvate, 100 U/ml penicillin, 100 ug/ml 
streptomycin and 50 ug/ml gentamycin (Invitrogen-Life 
Technologies, Carlsbad, CA). 
 
Isolation of peripheral blood mononuclear cells 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from 
venous blood of HIV patients and normal human volunteers by 
buoyant density centrifugation over Ficoll-Paque gradient 
(Amersham Pharmacia Biotech, Piscataway, NJ). The aliquots of Mahajan et al.    
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the effector cells in 10% DMSO and 90% FBS were 
cryopreserved in vapor phase of liquid nitrogen for future use in 
functional testing and FACS Analysis. 
 
Labeling of target cells with PKH67 
 
To discriminate between effector and target cells, the 8E5/LAV 
target cells are labeled with PKH67, a green fluorescent probe, 
(Sigma, St. Louis, MO) which becomes incorporated into the 
plasma membrane. 1million target LAV/8E5 cells are washed in 
PBS and resuspended in 250 ul of Solution C from the PKH67 
green fluorescent cell linker kit. The PKH67 dye is diluted to 4 
X10-6 M in 250 µl of solution C. The Cells are combined with the 
dye and the tube inverted several times without vortexing for 3-5 
mins. 500 µl of FCS is then added and the tube is mixed for 
another 1 min. Cells are then washed 3 times with phenol-red 




Effector cells (PBMC isolated from HIV patients and normal 
controls) are stimulated with PMA (25 ng/ml) and calcium 
ionophore (50ng/ml), and rIL-2 (20U/ml) are incubated at 37°C, 
5% CO2 for a period of 7 days for CTL induction. CTLs can be 
generated from precursor T lymphocytes following polyclonal 
activation induced by activating lymphokines such as IL-2. IL-2 
activated cytotoxic cells are usually referred to as lymphokine 
activated killer cells (LAK). LAK cells derived from peripheral 





After the CTL induction process the effector cells are mixed with 
a fixed number (104 cells) of PKH67 labeled target cells at 
various E:T ratios of 1:1. 10:1, 25:1 and 50:1. The effector and 
targets are incubated together at 370C, 5% CO2 for 4 hours, at 
the end of the incubation cells are fixed, permeabilised (for 
intracellular granzyme B staining) and washed with PBS three 
times. Cells labeled with phycoerythrin conjugated anti 
Granzyme B antibody (Pelicluster Inc, Amsterdam, Clone GB11) 
and phycoerythrin conjugated Annexin-V in separate tubes. Cells 
are incubated in dark on ice for 30 minutes. Appropriate Isotype 
control (IgGк1) is included in all experiments. The viability of the 
PBMC, which were retrieved from liquid nitrogen storage, was 




The Annexin V (BD Pharmingen, Inc.) and 7-ADD (Sigma) 
staining by the target cells was quantitated by using an R1 gate 
specific for the target cell population, while the Granzyme B 
release by the effector cells was quantitated by using a R2 gate on 
the effector cell population, when samples were analysed on a 
FACScan flow cytometer (Becton Dickinson). A minimum of 
5000 events were gated and analyzed using R1 as a gate for the 
target cells alone and R2 as a gate for the effector cells alone. FL-
1 at 530/30nm quantitated PKH-67 and FL-2 at 585/42 nm 
quantitated PE labeled Granzyme B and Annexin V. Percentage 
of target cells expressing Annexin V/7-ADD and the percentage 
of effector cells expressing Granzyme B were calculated. Annexin 
V/7-ADD expression reflected cell death among the PKH67 
stained target cells and the percentage of effector cells stained 
with PE conjugated anti Granzyme B reflected the increased 
cytotoxic activity as the ratio of effector to target cells increases.  
 
Further to establish which population of the effector cells were 
contributing to the cytotoxic activity, a separate experiment was 
conducted to quantitate the effector cells which stained positive 
for either/or PE labeled CD8/CD69 monoclonal anti bodies, a 
minimum of 2500 events were collected and analyzed. The 
percentage cytotoxic activity induction by the effector cell 
population in the PBMC could thus be attributed to CD8 cells or 
NK cells. Using this methodology we analyzed a total of 10 
samples in each group, from patients with active HIV disease and 




Data are expressed as the Mean + SD. Statistical significance was 
determined using paired two-tailed Student’s t-test. Differences 
were considered statistically significant for p<0.05 (Shown in 
asterisks in figures). Statistical analysis was performed using the 




The method outlined in this manuscript is a flow cytometric assay 
where gating is based on the difference in florescence of target 
cells before and after labeling with PKH67, a green fluorescent 
probe that gets incorporated into the plasma membrane of the 
target cells. Figure 1 shows the target and effector cells together 
and the gates being used for FACS Analysis. The PKH67 labeled 
LAV/8E5 (target cells) are gated using gate R1 and the unlabelled 
PBMC (effector cells) are gated using gate R2. 
 
 
Fig. 1: Shows R1 gate around the Target cells, and R2 gate around the 
Effector cells. The Target cells are labeled with PKH 67 and represented on the 
Y axis (FL-1), X-axis represents side scatter. Mahajan et al.    
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Annexin-V and 7ADD positive cells among the 
gated target cells stained with PKH67 dye 
 
Apoptosis or cell death is characterized by a variety of 
morphological changes like changes in the plasma membrane. 
Annexin-V staining precedes the loss of membrane integrity 
which accompanies the latest stages of cell death resulting from 
apoptosis. Annexin-V in conjunction with 7-amino-actinomycin 
D helps identify early apoptotic cells. 7ADD is used to evaluate 
the increased membrane permeability of target cells due to the 
granzyme mediated cytotoxic action of effector cells. Data at the 
end of the four-hour cytotoxicity a s s a y ,  d e p i c t e d  i n  F i g u r e  2  
shows that on gating target cells alone (R1), there is a significant 
increase in Annexin-V and 7ADD staining of target cells as the 
effector cells to target cell ratio increases, the increase in 
Annexin-V binding was from 9.5%, 18.26%, 34.39 and 42.19% at 
an E: T ratios of 1:1, 10:1, 25:1 and 50:1 respectively, and an 
similar increase in 7ADD binding was from 7.52%, 17.85%, 
29.16 and 42.10% at an E:T ratios of 1:1, 10:1, 25:1 and 50:1 
respectively were observed, both data suggesting a increase 




Fig. 2: Representative FACS analysis data showing the percentage of 
staining of Annexin-V / and 7-ADD from the target cells and using an R1 
gate after the 4 hr cytotoxicity assay with E: T ratios of 1:1, 10:1, 25:1 and 




Granzyme B expression by effector PBMC in 
normal and HIV subjects 
 
Figure 3 indicates the increase in Granzyme B expression in the 
effector PBMCs from normal controls and HIV subjects, the 
granzyme B expression in normal controls was 0.98%, 3.87%, 
6.25% and 6.76% and in HIV subjects was 3.15%, 9.28%, 
13.72% and 16.49% at an E:T ratios of 1:1, 10:1, 25:1 and 50:1 




Fig. 3: Representative FACS analysis data from normal and HIV patient 
showing granzyme B expression. A: Shows Isotype control (IgGk1) used for 
setting the regions. Figure B a, b, c, d and Figure C a, b, c, d shows the percentage 
of Granzyme B release from the effector cells   of normal controls and the HIV 
patients using an R2 gate after the 4 hr cytotoxicity assay with E: T ratios of 1:1, 
10:1, 25:1 and 50:1 respectively. Percent Granzyme B expression is represented 
on the FL-2 axis (PE). 
 
 
Fig. 4: Histogram representation of the percent Granzyme B expression in 
HIV subjects and normal controls as measured by the Granzyme B release 
CTL assay. Data presented is the mean + SD of 3 experiments where the total 
of 10 subjects in each group. Mahajan et al.    
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Figure 4 shows data from HIV patients (n=10) and normal non-
HIV controls (n=10) which shows that there is a significantly 
enhanced CTL response as measured by the percent granzyme B 
release by the effector cells (R2 gate) in HIV infected subjects as 
compared to the normal non-HIV controls. The mean granzyme 
B expression in HIV subjects was 3.15 + 0.71%, 8.28 + 1.1 %, 
14.2 + 2.5% and 17.12 + 2.9% at an E: T ratios of 1:1, 10:1, 25:1 
and 50:1 respectively while the mean granzyme B expression in 
non-HIV control subjects was 0.45 + 0.37%, 4.66 + 1.4 %, 6.41 
+ 1.3% and 6.99 + 1.6% at an E: T ratios of 1:1, 10:1, 25:1 and 
50:1 respectively Data presented is the mean + SD of 3 
experiments where the total of 10 subjects in each group. 
Statistical analysis of the data indicated that the % granzyme B 
expression at E: T ratio of 1:1, 10:1 25:1 and 50: 1 were 
significantly higher (p<0.05, p<0.01, and p>0.0001) respectively 
in HIV subjects as compared to normal non-HIV controls. 
Further, data presented in Figure 5 shows that the HIV infected 
subjects showed significantly higher CD8 (39.2 + 2.44 %) 
(P<0.01), and CD69 (6.88+1.2 %) (p<0.05), expression as 
compared to the control group [(CD8) 16.8+1.96%), (CD69) 
(2.43+0.32%)] indicating a heightened immune response. 
 
 
Fig. 5: Representative histogram of the percent CD8 and CD69 (NK cells) 
expression in the effector cells in HIV subjects and normal controls as 
measured by flow cytometry. Data presented is the mean + SD of 3 
experiments where the total of 10 subjects in each group. 
 
Data presented is the mean + SD of 3 experiments where the 
total of 10 subjects in each group. There exist a positive 
correlation (Correlation coefficient r=+0.959) between the ratio 
of the effector cells and the percentage of Annexin V positive 
cells, and the also a positive correlation between Annexin V and 




Several methodologies exist for quantitation of active-reactive T 
cells in peripheral blood mononuclear cells, but many of the T 
cell assays are technically difficult to perform (3). The classical 51 
Chromium – release cytotoxic T cell (CTL) assays are 
cumbersome and difficult to quantitate reproducibly. Other 
methods like the detection of specific T cell – using MHC-
peptide tetrameric complexes are highly sensitive, but require 
knowledge of MHC type and prior identification of T cell 
epitopes. The responses to a complex antigen such as HIV 
involves T-cell clonotypes specific for a number of different 
MHC- peptides combinations that are different in each 
individual. These drawbacks are overcome by the use of 
functional assays such as ELISPOT or multiparameter cytokine 
flow cytometry analysis, that detect cytokine production by 
antigen specific T cells and also correlate with cytotoxic activity. 
Although the ELISPOT assay is an attractive alternative to the 
cumbersome 51Cr-release assay and tetramer assay and also 
measures cellular responses, they use an optical plate reader for 
sample analysis and are therefore restricted to one or two 
parameter detection, thus a multiparameter flow cytometry 
analysis is highly reproducible, less cumbersome and extremely 
reliable.  
 
The assay described in the present manuscript is based on the 
fact that cytotoxic T lymphocytes kill virus infected and tumor 
cell targets through the concerted action of proteins contained in 
cytolytic granules, primarily granzyme B. Granzymes are 
exogenous serine proteinases (enzymes) that are released from 
cytoplasmic granules of cytotoxic lymphocytes (CTLs) and NK 
cells (4). These granules contain next to granzymes other proteins 
including a pore-forming protein (Perforin). Upon binding of the 
CTL to a target cell (by CTL-receptor and antigen-presenting 
MHC molecules on the target cell) the contents of the granules 
are released in the intercellular space where after perforine will 
“perforate” the target cell membrane by forming transmembrane 
pores. Through these pores the granzymes can now enter the 
cytosol of the target cell. Granzyme B activates the intracellular 
cascade of caspases finally resulting in the killing of the target 
cells. The percentages of granzyme B positive effector cells can 
be determined by flow cytometry. In a cell undergoing apoptosis, 
loss of cell membrane integrity is a very late event usually 
preceded by the destructive action of endogenous cellular 
enzymes (10). The ability to exclude viable dyes such as trypan 
blue, propidium iodide (PI) or 7-aminoactinomycin D (7AAD) is 
a property of cells that have an intact plasma membrane. Cells in 
the early phases of apoptosis fall into this category. The utility of 
annexin V in flow cytometry applications is derived from its 
selective affinity for negatively charged phospholipids (11, 12). 
Annexin V can selectively bind to cells with a compromised 
membrane phospholipid asymmetry and this property has been 
exploited to identify populations of cells undergoing apoptosis 
from the target cell population.  
 
The fact that from very early stages of HIV-1 infection a large 
number of killing competent T lymphocytes are present in blood, 
supports the premise that CTL act as mediators of destruction of 
immune function during HIV infection. Since granzyme B 
constitutes the major effector molecule within effector cytotoxic 
T lymphocytes that induce apoptosis and lysis of virally infected 
cells, a method such as the one outlined is clearly very important 
in the assessment of immune response of the HIV patient 
undergoing antiretroviral therapy. Mahajan et al.    
 
 




A reliable procedure to measure antigen specific T cell response 
is required in a number of clinical vaccine trials to determine the 
efficacy of vaccines and immunotherapies. Study of HIV-specific 
C T L s  i n  v a r i o u s  s t a g e s  o f  d i s e ase provides important insights 
into AIDS pathogenesis and ultimately may lead to development 
of effective vaccine strategies. This method not only helps 
quantitate the CTL activity but also identifies the phenotype of 
the cells elucidating this immune response. Yet another 
important application of this method is to measure antitumoral 
immune response in immunocompetent individuals since 
cytotoxic T lymphocytes represent a major mechanism of the 
antitumoral immune response. Thus the potential use of this 
methodology for monitoring immunological responses is 
enormous, particularly in view of the fact that the method is 
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1. Cell culture 
 
8E5/LAV cells were cultured in phenol-red free RPMI 1640 complete media supplemented with 10% FCS, 2mM glutamine, 1mM 
pyruvate, 100 U/ml penicillin, 100 ug/ml streptomycin and 50 ug/ml gentamycin.  
 
2. Isolation of peripheral blood mononuclear cells 
 
1.  Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by buoyant density centrifugation over Ficoll-
HyPaque gradient. 
2.  Whole blood (10ml) was diluted with equal volume of Hanks balanced salt solution and then slowly layered over 5 ml of Ficoll.  
3.  Cells are centrifuged at 1800 rpm for 30 minutes in a refrigerated centrifuge. 
4.  The PBMC present in the cloudy interface are then transferred to another sterile culture tube and washed with Hanks balanced salt 
solution and centrifuged at 3000rpm for 10 minutes. This wash step is repeated thrice. 
5.  The isolated PBMC suspended at a concentration of 1million cells/ml in 10% DMSO and 90% FBS, aliquoted and were 
cryopreserved in vapor phase of liquid nitrogen for future use. 
 
3. Labeling of target cells with PKH67 
 
1.  LAV/8E5 cells {1 million/ml} are washed in PBS and resuspended in 250 µl of Solution C from the PKH67 green fluorescent cell 
linker kit.  
2.  PKH67 dye is diluted to 4 X10-6 M in 250 µl of solution C. 
3.  Cells are mixed with the dye and the tube inverted several times without vortexing for 3-5 mins.  
4.  500ul of FCS is then added and the tube is mixed for another 1 min.  
5.  Cells are then washed 3 times and then resuspended in with phenol-red free RPMI 1640 complete media. 
 
4. CTL induction 
 
1.  Cryopreserved PBMC (1million/ml) isolated from HIV patients and normal controls are quick thawed in a 37°C water bath and 
washed in PBS to remove the DMSO and then resuspended in warm phenol-red free RPMI 1640 complete culture media. 
2.  PBMC are stimulated with PMA (25 ng/ml), calcium ionophore (50ng/ml), and rIL-2 (20U/ml) and are incubated at 37°C, 5% 
CO2 for a period of 7 days for CTL induction. 
 
5. Cytotoxicity assay 
 
PBMC effector cells and the PKH67 labelled target cells are mixed at E:T ratios of 1:1, 10:1, 25:1, and 50:1  (shown in table below) and 
incubated together at 37°C, 5% CO2 for 4 hrs. 
 
Table 1: Cytotoxicity assay 
E:T ratio  PBMC (1000000 cells/ml) 
Volume added in µl 
PKH67 labelled LAV/8E5 cells 
(1000000 cells/ml) Volume added in µl 
1:1  10 µl (10000 cells)  10 µl (10000 cells) 
10:1  100 µl (100000 cells)  10 µl (10000 cells) 
25:1  250 µl (250000 cells)  10 µl (10000 cells) 
50:1  500 µl (500000 cells)  10 µl (10000 cells) 
 
6. FACS Analysis 
 
1.  After the cytotoxicity assay cells are fixed, permeabilised with BD Cytofix/CytopermTM Buffer   
2.  Cells washed with PBS three times.  
3.  Cells resuspended in staining buffer Dulbecco’s PBS with 3% heat inactivated FBS and 0.09% (w/v) sodium azide. 
4.  Cells labeled with phycoerythrin conjugated anti Granzyme B antibody (5 µl/tube) and phycoerythrin conjugated Annexin- V (5 
µl/tube) and Isotype control (IgGк1) (5 µl/tube) in separate tubes. 
5.  Cells incubated in dark on ice for 30mins. 
6.  Wash cells 1X by adding 1 ml of BD Perm/Wash buffer, centrifuge 5 mins at 3000rpm and discard supernatant. 
7.  Resuspend cells in 500 µl of staining buffer per tube. 
8.  Analyze stained cells with flow cytometer. 